Alvespimycin

Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 nM.

Product Specifications

CAS Number

[467214-20-6]

Product Name Alternative

17-DMAG; KOS-1022; NSC 707545

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/alvespimycin.html

Purity

99.52

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC

Molecular Formula

C32H48N4O8

Molecular Weight

616.75

Precautions

H315, H319, H335

References & Citations

[1]Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49 (15) :4606-15.|[2]Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116 (1) :45-53.|[3]Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel) . 2016 Aug 24;8 (9) . pii: E77.